Results 161 to 170 of about 450,783 (333)
Clinical Pharmacology of the Angiotensin Receptor Antagonists [PDF]
The Journal of Clinical Hypertension, 2001 openaire +2 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou +3 more
wiley +1 more source
Angiotensin II Receptor Antagonists [PDF]
Journal of Human Hypertension, 2001 openaire +2 more sources
Imidazole-Based AT<sub>1</sub> Receptor Ligands: Design, Synthesis and Pharmacological Evaluation. [PDF]
MoleculesDescamps F +5 more
europepmc +1 more source
FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran +10 more
wiley +1 more source
Heart Failure in Older Adults: Real-World Outcomes and Patient Profiles by Admission Service and Sex. [PDF]
J Clin MedBonanad C +10 more
europepmc +1 more source
Novel fluorescent angiotensin AT1 receptor antagonists
, 2012 © 2012 Dr. Marilena A. GiarrussoHypertension is a severe condition that affects many people worldwide. The pathophysiology of hypertension is unknown. Sartans (selective AT1 receptor antagonists) are known to be the most direct and widely used class of ...
Giarrusso, Marilena A.
core
Effects of AT1 and AT2 angiotensin receptor antagonists in angiotensin II-infused rats.
HYPERTENSION, 1998 Jin S. Li, R. Touyz, E. Schiffrin
semanticscholar +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source